Skip to main content
. Author manuscript; available in PMC: 2017 Nov 1.
Published in final edited form as: Surgery. 2016 Jul 14;160(5):1326–1332. doi: 10.1016/j.surg.2016.05.017

Figure 4.

Figure 4

Allelic Frequencies and Corresponding Tumor Regression Grade. Patients with at least one TS 3G allele were more likely to have complete or partial pathological response to 5-FU neoadjuvant therapy than patients without at least one 3G allele (OR 10.4, 95% CI 1.3–81.6) (p=0.01).